BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 28883691)

  • 21. HCC and Tumor Biomarkers: Does One Size Fits All?
    Ozgor D; Otan E
    J Gastrointest Cancer; 2020 Dec; 51(4):1122-1126. PubMed ID: 32827068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.
    Ahn JC; Teng PC; Chen PJ; Posadas E; Tseng HR; Lu SC; Yang JD
    Hepatology; 2021 Jan; 73(1):422-436. PubMed ID: 32017145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Possibilities of liquid biopsy in gastric cancer].
    Zakharenko AA; Zaitsev DA; Belyaev MA; Trushin AA; Ten OA; Natkha AS
    Vopr Onkol; 2016; 62(4):379-85. PubMed ID: 30474943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.
    Hu S; Liu Y; Yang Q; Chen L; Chai H; Xiao M; Qi C; Qiu W
    Invest New Drugs; 2023 Jun; 41(3):532-538. PubMed ID: 37099161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
    Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
    Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developments and current status of cell-free DNA in the early detection and management of hepatocellular carcinoma.
    Du S; Cao K; Yan Y; Wang Y; Wang Z; Lin D
    J Gastroenterol Hepatol; 2024 Feb; 39(2):231-244. PubMed ID: 37990622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
    Dhayat SA; Yang Z
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.
    Li X; Wang H; Li T; Wang L; Wu X; Liu J; Xu Y; Wei W
    Curr Probl Cancer; 2020 Apr; 44(2):100516. PubMed ID: 31836136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma.
    Temraz S; Nasr R; Mukherji D; Kreidieh F; Shamseddine A
    Expert Rev Mol Diagn; 2022 May; 22(5):507-518. PubMed ID: 35758097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid biopsy in liver cancer.
    Labgaa I; Villanueva A
    Discov Med; 2015 Apr; 19(105):263-73. PubMed ID: 25977189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liquid Biopsy in Hepatocellular Carcinoma: The Significance of Circulating Tumor Cells in Diagnosis, Prognosis, and Treatment Monitoring.
    Shaik MR; Sagar PR; Shaik NA; Randhawa N
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function.
    Okajima W; Komatsu S; Ichikawa D; Miyamae M; Kawaguchi T; Hirajima S; Ohashi T; Imamura T; Kiuchi J; Arita T; Konishi H; Shiozaki A; Moriumura R; Ikoma H; Okamoto K; Taniguchi H; Itoh Y; Otsuji E
    Oncotarget; 2016 Aug; 7(33):53820-53836. PubMed ID: 27462777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid biopsy for liver diseases.
    Mann J; Reeves HL; Feldstein AE
    Gut; 2018 Dec; 67(12):2204-2212. PubMed ID: 30177542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
    Rastogi A
    World J Gastroenterol; 2018 Sep; 24(35):4000-4013. PubMed ID: 30254404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma.
    Pinato DJ
    Oncogene; 2018 Aug; 37(34):4635-4638. PubMed ID: 29755128
    [No Abstract]   [Full Text] [Related]  

  • 36. Advances in Cancer Therapy: Liquid Biopsy.
    Marmé D
    Oncol Res Treat; 2017; 40(7-8):402-403. PubMed ID: 28728143
    [No Abstract]   [Full Text] [Related]  

  • 37. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
    Park S; Lee EJ; Rim CH; Seong J
    Yonsei Med J; 2018 Jun; 59(4):470-479. PubMed ID: 29749129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of liver biopsy in hepatocellular carcinoma.
    Di Tommaso L; Spadaccini M; Donadon M; Personeni N; Elamin A; Aghemo A; Lleo A
    World J Gastroenterol; 2019 Oct; 25(40):6041-6052. PubMed ID: 31686761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes.
    Mezzalira S; De Mattia E; Guardascione M; Dalle Fratte C; Cecchin E; Toffoli G
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma.
    Zhou J; Shi YH; Fan J
    Semin Oncol; 2012 Aug; 39(4):440-8. PubMed ID: 22846861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.